Reference 35 b(i) PET for Osophageal and Gastric Cancer
Positron emission tomography (PET) Oesophageal Gastric
Reference No. | 35bi |
| Reference Name | Positron emission tomography (PET) Oesophageal Gastric |
| Advisory Panels | Associate Professor Frederick Khafagi (Chair) (MSAC Member) Professor Brendon Kearney (Deputy Chair) (MSAC member until 31/12/08) Mr Brian Stafford (Consumer's Health Forum nominee) Dr Bryan Burmeister (Royal Australian and New Zealand College of Radiologists nominee) Mr Bernard Lyons (Royal Australian College of Surgeons nominee) Dr George Larcos (Australian and New Zealand Association of Physicians in Nuclear Medicine nominee) Dr Gabrielle Cehic (Medical Oncology Group of Australia Nominee) |
| Date Received by MSAC Secretariat | 30 June 2007 |
| Stage 1 - Eligibility | Eligible |
| Stage 2 - Assessment | Completed |
| Stage 3 - Formulation of Advice to the Minister | (i) MSAC has considered the safety, effectiveness and cost-effectiveness for positron emission tomography (PET) and PET/CT for the assessment of patients with primary cancer of the oesophagus or the gastro-oesophageal junction (GEJ) otherwise considered suitable for definitive treatment. MSAC finds PET is safe. MSAC finds that the addition of PET to the conventional staging of primary cancer of the oesophagus or the GEJ is clinically effective. MSAC finds that the addition of PET to the conventional staging of primary cancer of the oesophagus or the GEJ is likely to be cost saving. MSAC recommends public funding for the use of PET for the assessment of patients with primary cancer of the oesophagus or the GEJ considered suitable by conventional staging for definitive treatment. (ii) MSAC has considered the safety, effectiveness and cost-effectiveness for positron emission tomography (PET) and PET/CT for the assessment of residual oesophageal or GEJ cancer following definitive chemoradiation. MSAC finds PET is safe. MSAC finds that there are insufficient data to evaluate the effectiveness of PET for the assessment of residual oesophageal or GEJ cancer following definitive chemoradiation considered suitable for salvage surgery. A formal economic assessment was therefore not performed. MSAC does not recommend public funding for the use of PET in the assessment of residual oesophageal or GEJ cancer following definitive chemoradiation. (iii) MSAC has considered the evidence for safety, effectiveness and cost-effectiveness for positron emission tomography (PET) and PET/CT in addition to conventional staging including laparoscopy for the assessment of patients with biopsy proven primary gastric cancer otherwise considered potentially curable. MSAC finds PET is safe. MSAC finds that there are insufficient data to evaluate the effectiveness of PET assessment of patients with biopsy proven primary gastric cancer considered potentially curable. A formal economic assessment was therefore not performed. MSAC does not recommend public funding for the use of PET in the assessment of patients with biopsy proven primary gastric cancer otherwise considered potentially curable. |
| Stage 4 - Decision Noting of MSAC advice by the Minister does not constitute a final decision in relation to the provision of public funding | MSAC considered this assessment on 6 June 2008. The Minister noted MSAC's advice 28 August 2008. |
| Stage 5 - Implementation | 1 September 2009 |
Page currency, Latest update: 14 September, 2009
